No Data
China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.
Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.
Beigene's commercialized products for multiple indications are included in the new version of the national medical insurance drug list.
Beigene (06160) announced that its self-developed anti-PD-1 antibody drug, Baizean (Tiragolumab injection), and BTK inhibitor, Baiyueze (Zebutini capsule), have added three new indications and one indication has been included in the National Medical Insurance Catalog; Luye Pharma's co-introduced product, Baituowei (Goserelin injection microspheres), has added one indication included in the National Medical Insurance Catalog; Amgen's authorized introduced product, Kyprolis (Carfilzomib for injection), has successfully been renewed. The National Medical Insurance Catalog will be officially implemented starting January 1, 2025. This time the company's products Baizean and Baiyueze.
Three Luye Pharma Products Included in National Reimbursement Drug List
Luye Pharma Gains Ground With New Drug Inclusions
Luye Pharma (02186.HK): If the new drugs (including new indications) developed by Ruo Xinlin and others are included in the national medical insurance pharmaceutical directory for 2024.
Glory 11 Yue 28th luye pharma (02186.HK) announced that a variety of innovative products (including new indications) of the group have been successfully included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Pharmaceutical Catalog (2024)" ("2024 National Medical Insurance Drug Catalog"). This includes the first inclusion of Rosi Lin (Torodevindolafaxine hydrochloride sustained-release tablets); Beitawi (injection Gosheryl microspheres) newly included for breast cancer indications; and Lepusol (docetaxel liposomes for injection) included in the routine catalog. The new version of the National Medical Insurance Drug Catalog will be officially implemented starting January 1, 2025. The company believes
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
No Data
No Data
